{
    "2021-11-18": [
        [
            {
                "time": "2021-11-01",
                "original_text": "Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan",
                "features": {
                    "keywords": [
                        "Dicerna",
                        "Novo Nordisk",
                        "Takeover",
                        "Acquisition",
                        "$3.3 Billion"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "DICERNA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DRNA and Encourages Investors to Contact the Firm",
                "features": {
                    "keywords": [
                        "Investigation",
                        "Sale",
                        "DRNA",
                        "Investors"
                    ],
                    "sentiment_score": -0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "legal",
                        "investor relations"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "RNAi firm Dicerna Pharmaceuticals to be acquired for $3.3B",
                "features": {
                    "keywords": [
                        "RNAi",
                        "Dicerna Pharmaceuticals",
                        "Acquisition",
                        "$3.3B"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "Why Dicerna Pharmaceuticals Stock Is Rocketing Higher Today",
                "features": {
                    "keywords": [
                        "Dicerna Pharmaceuticals",
                        "Rocketing",
                        "Higher"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today",
                "features": {
                    "keywords": [
                        "DRNA",
                        "Novo Nordisk",
                        "Deal",
                        "Skyrocketing"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "Dicerna Stock Skyrockets as Novo Nordisk to Buy Research Partner for $3.3 Billion",
                "features": {
                    "keywords": [
                        "Dicerna",
                        "Novo Nordisk",
                        "Buy",
                        "Research Partner",
                        "$3.3 Billion"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Dicerna",
                        "Buyout",
                        "$3.3B"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Eli Lilly",
                        "Pfizer",
                        "Novo Nordisk"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "UPDATE 3-Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion",
                "features": {
                    "keywords": [
                        "Denmark",
                        "Novo Nordisk",
                        "Dicerna Pharma",
                        "$3.3 billion"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "Novo Nordisk strikes $3.3 billion deal to buy research partner Dicerna Pharmaceuticals",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Deal",
                        "Research Partner",
                        "Dicerna Pharmaceuticals",
                        "$3.3 billion"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion",
                "features": {
                    "keywords": [
                        "Denmark",
                        "Novo Nordisk",
                        "Dicerna Pharma",
                        "$3.3 billion"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "Novo Nordisk to Acquire Dicerna Pharmaceuticals in $3.3B Deal",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Acquire",
                        "Dicerna Pharmaceuticals",
                        "$3.3B"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "Novo Nordisk Agrees to Buy Dicerna Pharma for $3.3 Billion",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Agrees",
                        "Buy",
                        "Dicerna Pharma",
                        "$3.3 Billion"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}